Cortexa Therapeutics Founder Nathan Cole Nominated as ''Best Nonprofit Advocate'' by AZ Capitol Times
FOR IMMEDIATE RELEASECortexa Therapeutics Founder Nathan Cole Nominated for "Best Nonprofit Advocate" by Arizona Capitol TimesPublic voting is open through May 1 to recognize the active-duty Marine, father, and ALS patient advocate driving new hope through scienceSCOTTSDALE, Ariz. — April 21, 2026 — Cortexa Therapeutics today announced that founder Nathan Cole has been nominated for "Best Nonprofit Advocate" by the Arizona Capitol Times as part of its recognition of the Arizonans making a measurable impact
Cortexa Therapeutics Advances Target Validation as Phase 1b and Phase 2 Research Progress
FOR IMMEDIATE RELEASE Cortexa Therapeutics Advances Target Validation as Phase 1b and Phase 2 Research Progress Phoenix, Arizona – February 16, 2026 – Cortexa Therapeutics, Inc. today announced significant progress in its scientific validation roadmap, with Phase 1b and Phase 2 studies currently underway in collaboration with its contract research organization (CRO) partner in Scotland. These phases represent a critical advancement in validating Cortexa’s biological target and strengthening the
